<SEC-DOCUMENT>0001193125-25-289949.txt : 20251120
<SEC-HEADER>0001193125-25-289949.hdr.sgml : 20251120
<ACCEPTANCE-DATETIME>20251120165335
ACCESSION NUMBER:		0001193125-25-289949
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251120
DATE AS OF CHANGE:		20251120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXACT SCIENCES CORP
		CENTRAL INDEX KEY:			0001124140
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				200478229
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35092
		FILM NUMBER:		251503724

	BUSINESS ADDRESS:	
		STREET 1:		5505 ENDEAVOR LANE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719
		BUSINESS PHONE:		608-284-5700

	MAIL ADDRESS:	
		STREET 1:		5505 ENDEAVOR LANE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXACT CORP
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d37493ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 14A Information
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Proxy Statement Pursuant to Section&nbsp;14(a) of </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>the Securities Exchange Act of 1934 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(Amendment No.&#8195;) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>EXACT SCIENCES CORPORATION
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Registrant as
Specified In Its Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> <FONT STYLE="white-space:nowrap">and&nbsp;0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The following is a transcript of remarks delivered by Kevin Conroy, the President and Chief Executive
Officer of Exact Sciences Corporation, to employees of Exact Sciences Corporation on November&nbsp;20, 2025. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOOD MORNING. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS MORNING, WE ANNOUNCED THAT EXACT SCIENCES WILL BE ACQUIRED BY ABBOTT &#8212; A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">137-YEAR-OLD,</FONT></FONT> HEALTHCARE COMPANY THAT REACHES MORE THAN TWO BILLION PEOPLE EACH YEAR. TOGETHER, WE BECOME ONE OF THE LARGEST CANCER DIAGNOSTIC PROVIDERS IN HISTORY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I KNOW THIS ANNOUNCEMENT COMES AS A SURPRISE. IT&#8217;S A LOT TO TAKE IN, AND IT BRINGS A RANGE OF FEELINGS &#8212; PRIDE IN WHAT WE&#8217;VE BUILT, MIXED
WITH ANTICIPATION AND EXCITEMENT, AND MAYBE EVEN UNCERTAINTY, ABOUT THE FUTURE. I FEEL ALL OF THAT TOO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE THAN 16 YEARS, WE&#8217;VE STOOD
TOGETHER AS AN INDEPENDENT, MISSION-DRIVEN COMPANY &#8212; UNITED BY A POWERFUL PURPOSE: TO HELP ERADICATE CANCER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SINCE MY FIRST MEETING WITH DR. DAVE
AHLQUIST AT THE MAYO CLINIC IN 2009, WE&#8217;VE GROWN INTO A COMPANY THAT HAS SERVED MORE THAN 25 MILLION PATIENTS THROUGH OUR CANCER AND GENETIC TESTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS HAPPENED BECAUSE OF YOU &#8212; YOUR COMMITMENT, PASSION, AND RELENTLESS GRIT. YOU&#8217;VE CHANGED LIVES, SUPPORTED PATIENTS, EACH OTHER, AND OUR
MISSION EVERY SINGLE DAY. I&#8217;M DEEPLY GRATEFUL FOR THAT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OUR GOALS HAVE ALWAYS BEEN CLEAR: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TO REDUCE CANCER MORTALITY &#8212; AND WE&#8217;RE DOING THAT. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TO BE A GREAT PLACE TO WORK &#8212; AND WE ARE ONE. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TO BECOME AN ICONIC COMPANY &#8212; AND TOGETHER, WE ARE ACHIEVING THAT. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABBOTT APPROACHED US BECAUSE OF WHAT YOU HAVE BUILT. THEY ADMIRE OUR SCIENCE, OUR TECHNOLOGY, AND MOST OF
ALL, OUR PEOPLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THEY&#8217;RE ONE OF THE MOST RESPECTED HEALTHCARE COMPANIES IN THE WORLD &#8212; A $42 BILLION GLOBAL LEADER IN MEDICAL DEVICES,
DIAGNOSTICS, NUTRITIONAL PRODUCTS AND MEDICINES. THEY&#8217;RE KNOWN FOR INNOVATION, IMPACT AND AN EXCEPTIONAL REPUTATION AS A GREAT PLACE TO WORK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EACH
YEAR, ABBOTT HELPS MORE THAN TWO BILLION PEOPLE LIVE HEALTHIER, FULLER LIVES. BY JOINING FORCES, OUR WORK IN CANCER DETECTION, TREATMENT GUIDANCE, AND GENETIC TESTING HAS THE POTENTIAL TO REACH PATIENTS ON A TRULY GLOBAL SCALE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMPORTANTLY, ABBOTT DOES NOT HAVE WHAT WE HAVE IN CANCER DIAGNOSTICS OR GENETICS. THAT&#8217;S WHY THIS COMBINATION MATTERS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">UPON CLOSING WE WILL OPERATE AS A STANDALONE CANCER DIAGNOSTICS BUSINESS UNIT WITHIN ABBOTT. TOGETHER, WE&#8217;LL PLAN TO BUILD THE WORLD&#8217;S MOST
IMPACTFUL CANCER DIAGNOSTICS COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, YOU&#8217;RE PROBABLY WONDERING WHAT THIS MEANS FOR YOU. THE COMBINATION IS EXPECTED TO CLOSE IN THE SECOND
QUARTER OF 2026. UNTIL THEN, WE WILL REMAIN AN INDEPENDENT COMPANY AND VERY LITTLE WILL CHANGE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">YOUR WORK, REPORTING STRUCTURE, PAY, AND BENEFITS ARE NOT
CHANGING TODAY AS A RESULT OF THIS ANNOUNCEMENT. OUR 2025 BONUS, ANNUAL COMPENSATION INCREASES, 401K MATCH FOR 2025, AND PROMOTION CYCLE WILL CONTINUE AS PLANNED IN EARLY 2026. OUR ANNUAL STOCK AWARD GRANTS WILL ALSO OCCUR IN THE FIRST QUARTER OF
2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABBOTT AGREED TO CERTAIN PROTECTIONS FOR COMPENSATION AND BENEFITS THROUGH THE END OF 2026. ALL UNVESTED RESTRICTED STOCK UNITS THAT WERE GRANTED
BEFORE TODAY AND THAT ARE OUTSTANDING AT CLOSING WILL VEST AT THE TIME OF DEAL COMPLETION. THIS REFLECTS A RECOGNITION OF YOUR INSPIRED EFFORTS OVER THE LAST FEW YEARS AND IS A STRONG MOTIVATOR FOR THE HARD WORK TO COME. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WE EXPECT TO CONTINUE OPERATING FROM OUR LABS AND FACILITIES IN WISCONSIN, CALIFORNIA, ARIZONA, AND
INTERNATIONALLY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OUR HEADQUARTERS WILL STAY RIGHT HERE IN MADISON, WISCONSIN &#8212; THE HEART OF EXACT SCIENCES AND THE PLACE WHERE THIS INCREDIBLE
JOURNEY BEGAN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABBOTT&#8217;S HEADQUARTERS ARE JUST ABOUT 100 MILES AWAY, IN BETWEEN CHICAGO AND MILWAUKEE&#8212; A CLOSENESS THAT WILL MAKE IT EVEN
EASIER FOR OUR TEAMS TO STAY CONNECTED AND COLLABORATE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABBOTT DOES NOT HAVE THE CANCER DIAGNOSTICS AND CLINICAL LAB CAPABILITIES THAT WE DO &#8212; AND
THAT&#8217;S ONE OF THE MANY REASONS THEY VALUE WHAT WE BRING TO THE TABLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MOST IMPORTANTLY, OUR MISSION STAYS THE SAME. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WE REMAIN COMMITTED TO PATIENTS, HEALTH CARE PROVIDERS, AND PARTNERS WHO SHARE OUR BELIEF IN THE IMPORTANCE OF OUR WORK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS HAS BEEN ONE OF OUR BEST YEARS &#8212; RECORD PERFORMANCE AND IMPACT ON PATIENTS, THE LAUNCH OF THREE NEW PRODUCTS, AND INCREDIBLE TEAMWORK ACROSS THE
COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BUT WHEN YOU BUILD SOMETHING GREAT, PEOPLE NOTICE. AND WHEN A COMPANY LIKE ABBOTT REACHES OUT WITH AN OPPORTUNITY TO ACCELERATE THAT IMPACT,
IT&#8217;S BECAUSE THEY SEE WHAT WE SEE &#8212; A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ONCE-IN-A-GENERATION</FONT></FONT></FONT> OPPORTUNITY TO CHANGE THE COURSE OF CANCER. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABBOTT&#8217;S CEO, ROBERT FORD, HAS TAKEN THE TIME TO UNDERSTAND OUR MISSION AND THE IMPORTANT WORK WE DO.
ROBERT AND THE ABBOTT TEAM RECOGNIZE THE VALUE OF OUR SCIENCE, OUR PEOPLE, AND OUR EXACTNEXXUS PLATFORM. I HAVE TREMENDOUS RESPECT FOR ROBERT, FOR ABBOTT AS AN ORGANIZATION, AND FOR THEIR CULTURE AND MISSION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHILE WE HAVE ACCOMPLISHED SO MUCH AS AN INDEPENDENT COMPANY, THE BOARD DETERMINED THAT IT IS IN THE BEST INTEREST OF OUR SHAREHOLDERS TO MOVE FORWARD WITH
THIS $23 BILLION COMBINATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I WON&#8217;T PRETEND THIS IS EASY. INDEPENDENCE HAS BEEN PART OF OUR IDENTITY &#8212; AND LETTING GO OF THAT BRINGS MIXED
EMOTIONS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHAT GROUNDS ME IS GRATITUDE &#8212; FOR WHAT WE&#8217;VE BUILT, FOR THIS TEAM THAT MADE IT POSSIBLE, AND FOR THE MILLIONS OF LIVES WE&#8217;VE
CHANGED AND WILL CHANGE TOGETHER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JOINING ABBOTT DOESN&#8217;T DIMINISH OUR MISSION &#8212; IT AMPLIFIES IT. THEY RESPECT WHAT WE&#8217;VE BUILT AND WANT
TO HELP US DO MORE &#8211; FASTER, AND FOR MORE PATIENTS AROUND THE WORLD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WE&#8217;LL HAVE A STRONG PRESENCE WITHIN ABBOTT, IN A NEW AREA OF DIAGNOSTICS
FOR THEM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SO WHAT&#8217;S NEXT? OVER THE NEXT SEVERAL WEEKS, WE WILL IDENTIFY AN INTEGRATION PLANNING TEAM TO ENSURE WE&#8217;RE PREPARED FOR A SMOOTH
TRANSITION. WE DON&#8217;T HAVE ALL THE ANSWERS TODAY, BUT WE&#8217;LL SHARE AS MUCH AS WE CAN OPENLY IN THE COMING WEEKS AND MONTHS SO YOU ARE INFORMED EVERY STEP OF THE WAY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">YOU CAN EXPECT CLEAR, FREQUENT COMMUNICATION &#8212; AND IF YOU HAVE QUESTIONS, PLEASE ASK THEM. WE WANT YOU TO FEEL INFORMED AND CONFIDENT ABOUT WHAT&#8217;S
AHEAD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THANK YOU FOR YOUR UNWAVERING COMMITMENT TO THIS MISSION, YOUR PASSION, AND YOUR HEART. YOU ARE THE REASON WE&#8217;VE COME THIS FAR &#8212; AND
THE REASON WE&#8217;LL GO EVEN FURTHER. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">YES, THERE WILL BE CHANGE AHEAD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BUT THE CORE OF EXACT SCIENCES &#8212; OUR PEOPLE, OUR PURPOSE, AND OUR DRIVE TO MAKE A DIFFERENCE &#8212; WILL NOT CHANGE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WE ARE STILL THE TEAM THAT TAKES ON THE IMPOSSIBLE, THE TEAM THAT TURNS IDEAS INTO LIFE-CHANGING TESTS, AND THE TEAM THAT STANDS SHOULDER TO SHOULDER TO
CHANGE LIVES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">YOUR WORK MATTERS NOW MORE THAN EVER. LET&#8217;S CONTINUE TO SUPPORT EACH OTHER AND OUR PATIENTS &#8212; AS WE ALWAYS HAVE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I AM SO PROUD AND SO HONORED TO BE PART OF THIS TEAM. THANK YOU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with the proposed transaction, Exact Sciences Corporation (&#8220;Exact Sciences&#8221;) will file with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) a proxy statement, the definitive version of which will be sent or provided
to Exact Sciences&#8217; stockholders. Exact Sciences may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Exact
Sciences with the SEC. INVESTORS AND SECURITY HOLDERS OF EXACT SCIENCES ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION. Investors and security holders will be able to obtain the proxy statement (when it is available) and other documents that are filed with the SEC by Exact Sciences free of charge from the SEC&#8217;s website at <U>https://www.sec.gov</U>
or through the investor relations section of Exact Sciences&#8217; website at <U>https://www.exactsciences.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exact Sciences and its directors and certain of its executive officers and other employees may be deemed to be participants in the solicitation of
proxies from Exact Sciences&#8217; stockholders in connection with the proposed transaction. Information about the directors and executive officers of Exact Sciences and their ownership of Exact Sciences common shares is contained in the definitive
proxy statement for Exact Sciences&#8217; 2025 annual meeting of shareholders, which was filed with the SEC on April&nbsp;29, 2025, including under the headings &#8220;Information Concerning Directors and Nominees for Director,&#8221;
&#8220;Information Concerning Executive Officers,&#8221; &#8220;Corporate Governance Principles, Board Matters, and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation,&#8221; &#8220;Compensation and Other Information
Concerning Named Executive Officers&#8221; and &#8220;Securities Ownership of Certain Beneficial Owners and Management.&#8221; Additional information regarding ownership of Exact Sciences&#8217; securities by its directors and executive officers is
included in such persons&#8217; SEC filings on Forms 3 and 4. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders of Exact Sciences in connection with the
proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be included in the proxy statement relating to the proposed transaction when it is filed with the SEC. Free copies of the
proxy statement relating to the proposed transaction and free copies of the other SEC filings to which reference is made in this paragraph may be obtained from the SEC&#8217;s website at <U>https://www.sec.gov</U> or through the investor relations
section of Exact Sciences&#8217; website at <U>https://www.exactsciences.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott Laboratories.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the
possible inability of the parties to consummate the proposed transaction on a timely basis or at all; the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including necessary
regulatory approvals and the requisite vote by Exact Sciences&#8217; stockholders, on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the parties&#8217;
definitive agreement for the proposed transaction (the &#8220;Merger Agreement&#8221;); the risk that the Merger Agreement may be terminated in circumstances that require Exact Sciences to pay a termination fee; the possibility that competing offers
may be made; the potential adverse impact on Exact Sciences of contractual restrictions under the Merger Agreement that limit Exact Sciences&#8217; ability to pursue business opportunities or strategic transactions; risks relating to significant
transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated; potential adverse effects of the announcement or pendency of the proposed transaction,
or any failure to complete the proposed transaction, on the market price of Exact Sciences&#8217; common stock or on the ability of Exact Sciences to develop and maintain relationships with its personnel (including Exact Sciences&#8217; ability to
attract and retain highly qualified management and other scientific personnel) and customers, suppliers and others with whom it does business or otherwise on Exact Sciences&#8217; business, financial condition, results of operations and financial
performance; risks related to diversion of management&#8217;s attention from Exact Sciences&#8217; ongoing business operations due to the proposed transaction; and the risk of litigation and/or regulatory actions related to the proposed transaction
or Exact Sciences&#8217; business and the outcome of any such litigation or regulatory action.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risks described above are not exhaustive. Other
important risks and uncertainties affecting Exact Sciences and its business are described in the Risk Factors sections of Exact Sciences&#8217; most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent
Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and in its other reports filed with the SEC. Exact Sciences undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future developments or otherwise. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
